ArticleAntimicrobial agents and chemotherapy2017
Activity of the β-Lactamase Inhibitor LN-1-255 against Carbapenem-Hydrolyzing Class D β-Lactamases from Acinetobacter baumannii.
Open access · bronzeAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Zwitterionic Penicillin-Derived Sulfone Inhibitor for Combating β-Lactamase-Mediated Antibiotic Resistance.ChemMedChem · 2026Article
- Disarming carbapenemase-producingAntimicrobial agents and chemotherapy · 2026Article
- Antibacterial activity of enmetazobactam againstAntimicrobial agents and chemotherapy · 2026Article
- Functional and structural analyses of amino acid sequence variation in PDC β-lactamase reveal different mechanistic pathways toward cefiderocol resistance inAntimicrobial agents and chemotherapy · 2025Article
- Molecular characterization of carbapenem-resistant and carbapenem-sensitiveFrontiers in microbiology · 2025Article
- Novel Penicillin-Based Sulfone-Siderophore Conjugates for Restoring β-Lactam Antibiotic Efficacy.ACS omega · 2024Article
- A review on the mechanistic details of OXA enzymes of ESKAPE pathogens.Pathogens and global health · 2023Review
- Sulfonamidoboronic Acids as "Cross-Class" Inhibitors of an Expanded-Spectrum Class C Cephalosporinase, ADC-33, and a Class D Carbapenemase, OXA-24/40: Strategic Compound Design to Combat Resistance inAntibiotics (Basel, Switzerland) · 2023Article
- The role of adjuvants in overcoming antibacterial resistance due to enzymatic drug modification.RSC medicinal chemistry · 2022Review
- Review
- Inhibition of theACS infectious diseases · 2021Article
- Activity of Imipenem, Meropenem, Cefepime, and Sulbactam in Combination with the β-Lactamase Inhibitor LN-1-255 againstAntibiotics (Basel, Switzerland) · 2021Article
- Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment ofFrontiers in microbiology · 2021Review
- New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams.International journal of molecular sciences · 2020Review
- Article
- Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It.Molecules (Basel, Switzerland) · 2020Review
- Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii.Antimicrobial agents and chemotherapy · 2019Article
- New Treatment Options against Carbapenem-ResistantAntimicrobial agents and chemotherapy · 2019Review
- β-lactam/β-lactamase inhibitor combinations: an update.MedChemComm · 2018Review
- Comparison of Septic Shock Due to Multidrug-Resistant Acinetobacter baumannii or Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Intensive Care Unit Patients.Antimicrobial agents and chemotherapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Juan Carlos Vázquez-UchaServicio de Microbiología-Instituto de Investigación Biomédica (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
María ManeiroCentro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS) and Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
Marta Martínez-GuitiánServicio de Microbiología-Instituto de Investigación Biomédica (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
John BuynakDepartment of Chemistry, Southern Methodist University, Dallas, Texas, USA.
Christopher R BethelResearch Service, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Robert A BonomoResearch Service, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Germán BouServicio de Microbiología-Instituto de Investigación Biomédica (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
Margarita PozaServicio de Microbiología-Instituto de Investigación Biomédica (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
Concepción González-BelloCentro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS) and Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
Alejandro BeceiroServicio de Microbiología-Instituto de Investigación Biomédica (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain Alejandro.Beceiro.Casas@sergas.es.
Complexo Hospitalario Universitario A Coruña · ESLouis Stokes Cleveland VA Medical Center · USCenter for Research in Molecular Medicine and Chronic Diseases · ESInstituto de Investigación Biomédica de A Coruña · ESSouthern Methodist University · USUniversidade de Santiago de Compostela · ES
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4MUnderstanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6MUnderstanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9MA Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4MBicyclic beta-Lactam Antibiotics as Poor Substrates for Metallo-beta-lactamasesR15AI109624 · NIAID · SOUTHERN METHODIST UNIVERSITY · PI BUYNAK, JOHN D · 2014 to 2014
$438kThe Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–BLRD VA I01 BX001974NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIAID NIH HHS R15 AI109624NIGMS NIH HHS T32 GM007250
Abstract
The number of infections caused by Gram-negative pathogens carrying carbapenemases is increasing, and the group of carbapenem-hydrolyzing class D β-lactamases (CHDLs) is especially problematic. Several clinically important CHDLs have been identified in
Indexed as
Acinetobacter baumanniiAzabicyclo Compoundsbeta-Lactamase Inhibitorsbeta-LactamasesCarbapenemsCatalytic DomainCephalosporinsCyclic S-OxidesHumansHydrolysisMicrobial Sensitivity TestsMolecular Docking SimulationPenicillanic AcidPenicillinsTazobactamavibactamAzabicyclo Compoundsbeta-Lactamase Inhibitorsbeta-lactamase OXA-24beta-lactamase OXA-51, Acinetobacter baumanniibeta-LactamasesCarbapenemsCephalosporinsCyclic S-OxidesLN 1-255nitrocefinPenicillanic AcidPenicillinsTazobactamAcinetobacter baumanniiantimicrobial resistancecarbapenem-hydrolyzing class D β-lactamasesβ-lactamase inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.